232 related articles for article (PubMed ID: 32268773)
1. Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors.
Itonaga T; Saito K; Ikeda N; Mikami R
Acta Radiol; 2021 Jan; 62(1):42-50. PubMed ID: 32268773
[TBL] [Abstract][Full Text] [Related]
2. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
[TBL] [Abstract][Full Text] [Related]
3. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
[TBL] [Abstract][Full Text] [Related]
6. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
7. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
8. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
9. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
10. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
Zhang X; Wu Y; Lv J; Li X; Ma L; Nong J; Zhang H; Qin N; Zhang Q; Shi G; Yang X; Wang J; Zhang S
Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST
Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528
[TBL] [Abstract][Full Text] [Related]
14. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Seike M; Gemma A; Nishio M
BMC Cancer; 2020 Mar; 20(1):207. PubMed ID: 32164651
[TBL] [Abstract][Full Text] [Related]
15. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer.
Fuschillo S; Battiloro C; Rocco D; D Gravara L; Motta A; Maniscalco M
Biomark Med; 2020 Jul; 14(11):929-932. PubMed ID: 32940076
[No Abstract] [Full Text] [Related]
17. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Melosky B; Chu Q; Juergens RA; Leighl N; Ionescu D; Tsao MS; McLeod D; Hirsh V
Cancer Treat Rev; 2018 Apr; 65():65-77. PubMed ID: 29567557
[TBL] [Abstract][Full Text] [Related]
18. Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
Inomata M; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Ichikawa T; Imanishi S; Yamada T; Miwa T; Hayashi R; Tobe K
Pathol Oncol Res; 2020 Jan; 26(1):327-333. PubMed ID: 30232703
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
Zhou N; Velez MA; Bachrach B; Gukasyan J; Fares CM; Cummings AL; Lind-Lebuffe JP; Akingbemi WO; Li DY; Brodrick PM; Yessuf NM; Rettinger S; Grogan T; Rochigneux P; Goldman JW; Garon EB; Lisberg A
Lung Cancer; 2021 Nov; 161():34-41. PubMed ID: 34507111
[TBL] [Abstract][Full Text] [Related]
20. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
Qu J; Jiang M; Wang L; Zhao D; Qin K; Wang Y; Tao J; Zhang X
Biomed Pharmacother; 2020 Jul; 127():109996. PubMed ID: 32388240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
